Xeris Biopharma Holdings, Inc.

Securities Trading Plans of Directors and Executive Officers

On November 26, 2025, James Brady, a member of the Company's board of directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 21,667 shares of the Company's common stock. Mr. Brady’s Rule 10b5-1 trading arrangement was adopted in order to sell-to-cover a number of shares of the Company’s common stock to satisfy tax withholding obligations in connection with the vesting of Mr. Brady's restricted stock units. The trading arrangement is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The duration of the trading arrangement is until April 2, 2027, subject to the earlier termination as provided in the plan.

During the three months ended December 31, 2025, no other directors or officers of the Company adopted, materially modified, orterminated any contract, instruction, or written plan for the purchase or sale of Company securities under a "Rule 10b5-1 trading arrangement" or any "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(c) of Regulation S-K of the Exchange Act.